Empasiprubart is a novel, humanized, IgG1 monoclonal antibody that binds C2, thereby blocking downstream activation of both the classical and lectin complement pathways, while leaving the alternative pathway intact. Empasiprubart binds to C2 in a pH- and calcium-dependent manner and is engineered for increased affinity to FcRn to achieve a prolonged half-life.
(1) Empasiprubart binds C2 in circulation before being internalized into the cell
(2) C2 is released in the endosome
(3) Empasiprubart binds to FcRn
(4) Unbound C2 is degraded in the lysosome
(5) Empasiprubart escapes lysosomal degradation and is recycled back into circulation
(1) Empasiprubart binds C2 in circulation before being internalized into the cell
(2) C2 is released in the endosome
(3) Empasiprubart binds to FcRn
(4) Unbound C2 is degraded in the lysosome
(5) Empasiprubart escapes lysosomal degradation and is recycled back into circulation
